Safety trial of single-dose treatments with a combination of ivermectin and diethylcarbamazine in bancroftian filariasis.
Identifieur interne : 004F71 ( PubMed/Checkpoint ); précédent : 004F70; suivant : 004F72Safety trial of single-dose treatments with a combination of ivermectin and diethylcarbamazine in bancroftian filariasis.
Auteurs : J P Moulia-Pelat [Polynésie française] ; L N Nguyen ; P. Glaziou ; S. Chanteau ; V M Gay ; P M Martin ; J L CartelSource :
- Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit (GTZ) [ 0177-2392 ] ; 1993.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Animaux, Association médicamenteuse, Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (pharmacologie), Diéthylcarbamazine (usage thérapeutique), Facteurs temps, Filariose lymphatique (sang), Filariose lymphatique (traitement médicamenteux), Humains, Ivermectine (effets indésirables), Ivermectine (pharmacologie), Ivermectine (usage thérapeutique), Microfilaria (), Mâle, Porteur sain (sang), Porteur sain (traitement médicamenteux), Relation dose-effet des médicaments, Sujet âgé, Wuchereria bancrofti ().
- MESH :
- effets indésirables : Diéthylcarbamazine, Ivermectine.
- pharmacologie : Diéthylcarbamazine, Ivermectine.
- sang : Filariose lymphatique, Porteur sain.
- traitement médicamenteux : Filariose lymphatique, Porteur sain.
- usage thérapeutique : Diéthylcarbamazine, Ivermectine.
- Adulte, Adulte d'âge moyen, Animaux, Association médicamenteuse, Facteurs temps, Humains, Microfilaria, Mâle, Relation dose-effet des médicaments, Sujet âgé, Wuchereria bancrofti.
English descriptors
- KwdEn :
- Adult, Aged, Animals, Carrier State (blood), Carrier State (drug therapy), Diethylcarbamazine (adverse effects), Diethylcarbamazine (pharmacology), Diethylcarbamazine (therapeutic use), Dose-Response Relationship, Drug, Drug Combinations, Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Humans, Ivermectin (adverse effects), Ivermectin (pharmacology), Ivermectin (therapeutic use), Male, Microfilariae (drug effects), Middle Aged, Time Factors, Wuchereria bancrofti (drug effects).
- MESH :
- chemical , adverse effects : Diethylcarbamazine, Ivermectin.
- blood : Carrier State, Elephantiasis, Filarial.
- drug effects : Microfilariae, Wuchereria bancrofti.
- drug therapy : Carrier State, Elephantiasis, Filarial.
- chemical , pharmacology : Diethylcarbamazine, Ivermectin.
- chemical , therapeutic use : Diethylcarbamazine, Ivermectin.
- Adult, Aged, Animals, Dose-Response Relationship, Drug, Drug Combinations, Humans, Male, Middle Aged, Time Factors.
Abstract
A supervised safety trial of the treatment with a combination of ivermectin 400 micrograms.kg-1 (IVER 400) plus increasing doses of diethylcarbamazine (DEC), given simultaneously in single dose, was performed on five groups of Polynesian Wuchereria bancrofti carriers, 49 males aged 25 to 73 years, in whom microfilaremia ranged from 1 to 6,137 mf/ml. The trial was hospital-based, open, dose-escalating (1 group per week). Safety of an unchanging dose of IVER 400 and ascending doses of DEC were studied in the 5 following groups: group 1- IVER 400 plus DEC 1 mg.kg-1, 12 patients; group 2- IVER 400 plus DEC 3 mg.kg-1, 17 patients; group 3- IVER 400 plus DEC 6 mg.kg-1, 10 patients. Two control groups were included in the study, group 4- DEC 6 mg.kg-1 alone, 5 patients; group 5-: IVER 400 alone, 5 patients. Carriers were examined and questioned regarding their experience of adverse reactions, which were graded 0 to 3 according to severity, at 6, 12 and 24 hours and at 4 days after treatment. Biological examination was performed 4 days before and 4 days after treatment and included determination of microfilaremia, complete blood count, liver function tests and assessment of creatinine and urea levels. Adverse reactions were observed in 51% of 49 carriers (15 of grade 1, 8 of grade 2, 2 of grade 3). None was considered serious and they all disappeared in 2 days. The main symptoms were fever > or = 37.5 degrees C, myalgia, arthralgia, headache, asthenia, anorexia, vertigo and chills. Adverse reactions of patients were not significantly different between the five groups.(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed: 8367670
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:8367670Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety trial of single-dose treatments with a combination of ivermectin and diethylcarbamazine in bancroftian filariasis.</title><author><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name><affiliation wicri:level="1"><nlm:affiliation>Institut Territorial de Recherches Medicales Louis Malarde, Papeete, Tahiti, Polynesie Francaise.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Polynésie française</country><wicri:regionArea>Institut Territorial de Recherches Medicales Louis Malarde, Papeete, Tahiti</wicri:regionArea><wicri:noRegion>Tahiti</wicri:noRegion></affiliation></author><author><name sortKey="Nguyen, L N" sort="Nguyen, L N" uniqKey="Nguyen L" first="L N" last="Nguyen">L N Nguyen</name></author><author><name sortKey="Glaziou, P" sort="Glaziou, P" uniqKey="Glaziou P" first="P" last="Glaziou">P. Glaziou</name></author><author><name sortKey="Chanteau, S" sort="Chanteau, S" uniqKey="Chanteau S" first="S" last="Chanteau">S. Chanteau</name></author><author><name sortKey="Gay, V M" sort="Gay, V M" uniqKey="Gay V" first="V M" last="Gay">V M Gay</name></author><author><name sortKey="Martin, P M" sort="Martin, P M" uniqKey="Martin P" first="P M" last="Martin">P M Martin</name></author><author><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8367670</idno><idno type="pmid">8367670</idno><idno type="wicri:Area/PubMed/Corpus">005721</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005721</idno><idno type="wicri:Area/PubMed/Curation">005721</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005721</idno><idno type="wicri:Area/PubMed/Checkpoint">005721</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005721</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety trial of single-dose treatments with a combination of ivermectin and diethylcarbamazine in bancroftian filariasis.</title><author><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name><affiliation wicri:level="1"><nlm:affiliation>Institut Territorial de Recherches Medicales Louis Malarde, Papeete, Tahiti, Polynesie Francaise.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Polynésie française</country><wicri:regionArea>Institut Territorial de Recherches Medicales Louis Malarde, Papeete, Tahiti</wicri:regionArea><wicri:noRegion>Tahiti</wicri:noRegion></affiliation></author><author><name sortKey="Nguyen, L N" sort="Nguyen, L N" uniqKey="Nguyen L" first="L N" last="Nguyen">L N Nguyen</name></author><author><name sortKey="Glaziou, P" sort="Glaziou, P" uniqKey="Glaziou P" first="P" last="Glaziou">P. Glaziou</name></author><author><name sortKey="Chanteau, S" sort="Chanteau, S" uniqKey="Chanteau S" first="S" last="Chanteau">S. Chanteau</name></author><author><name sortKey="Gay, V M" sort="Gay, V M" uniqKey="Gay V" first="V M" last="Gay">V M Gay</name></author><author><name sortKey="Martin, P M" sort="Martin, P M" uniqKey="Martin P" first="P M" last="Martin">P M Martin</name></author><author><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name></author></analytic><series><title level="j">Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit (GTZ)</title><idno type="ISSN">0177-2392</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Animals</term><term>Carrier State (blood)</term><term>Carrier State (drug therapy)</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (pharmacology)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Combinations</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Humans</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (pharmacology)</term><term>Ivermectin (therapeutic use)</term><term>Male</term><term>Microfilariae (drug effects)</term><term>Middle Aged</term><term>Time Factors</term><term>Wuchereria bancrofti (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Association médicamenteuse</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (pharmacologie)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Facteurs temps</term><term>Filariose lymphatique (sang)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (pharmacologie)</term><term>Ivermectine (usage thérapeutique)</term><term>Microfilaria ()</term><term>Mâle</term><term>Porteur sain (sang)</term><term>Porteur sain (traitement médicamenteux)</term><term>Relation dose-effet des médicaments</term><term>Sujet âgé</term><term>Wuchereria bancrofti ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Carrier State</term><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Microfilariae</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carrier State</term><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Filariose lymphatique</term><term>Porteur sain</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Porteur sain</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Animals</term><term>Dose-Response Relationship, Drug</term><term>Drug Combinations</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Association médicamenteuse</term><term>Facteurs temps</term><term>Humains</term><term>Microfilaria</term><term>Mâle</term><term>Relation dose-effet des médicaments</term><term>Sujet âgé</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A supervised safety trial of the treatment with a combination of ivermectin 400 micrograms.kg-1 (IVER 400) plus increasing doses of diethylcarbamazine (DEC), given simultaneously in single dose, was performed on five groups of Polynesian Wuchereria bancrofti carriers, 49 males aged 25 to 73 years, in whom microfilaremia ranged from 1 to 6,137 mf/ml. The trial was hospital-based, open, dose-escalating (1 group per week). Safety of an unchanging dose of IVER 400 and ascending doses of DEC were studied in the 5 following groups: group 1- IVER 400 plus DEC 1 mg.kg-1, 12 patients; group 2- IVER 400 plus DEC 3 mg.kg-1, 17 patients; group 3- IVER 400 plus DEC 6 mg.kg-1, 10 patients. Two control groups were included in the study, group 4- DEC 6 mg.kg-1 alone, 5 patients; group 5-: IVER 400 alone, 5 patients. Carriers were examined and questioned regarding their experience of adverse reactions, which were graded 0 to 3 according to severity, at 6, 12 and 24 hours and at 4 days after treatment. Biological examination was performed 4 days before and 4 days after treatment and included determination of microfilaremia, complete blood count, liver function tests and assessment of creatinine and urea levels. Adverse reactions were observed in 51% of 49 carriers (15 of grade 1, 8 of grade 2, 2 of grade 3). None was considered serious and they all disappeared in 2 days. The main symptoms were fever > or = 37.5 degrees C, myalgia, arthralgia, headache, asthenia, anorexia, vertigo and chills. Adverse reactions of patients were not significantly different between the five groups.(ABSTRACT TRUNCATED AT 250 WORDS)</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8367670</PMID><DateCreated><Year>1993</Year><Month>10</Month><Day>07</Day></DateCreated><DateCompleted><Year>1993</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0177-2392</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>1993</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit (GTZ)</Title><ISOAbbreviation>Trop. Med. Parasitol.</ISOAbbreviation></Journal><ArticleTitle>Safety trial of single-dose treatments with a combination of ivermectin and diethylcarbamazine in bancroftian filariasis.</ArticleTitle><Pagination><MedlinePgn>79-82</MedlinePgn></Pagination><Abstract><AbstractText>A supervised safety trial of the treatment with a combination of ivermectin 400 micrograms.kg-1 (IVER 400) plus increasing doses of diethylcarbamazine (DEC), given simultaneously in single dose, was performed on five groups of Polynesian Wuchereria bancrofti carriers, 49 males aged 25 to 73 years, in whom microfilaremia ranged from 1 to 6,137 mf/ml. The trial was hospital-based, open, dose-escalating (1 group per week). Safety of an unchanging dose of IVER 400 and ascending doses of DEC were studied in the 5 following groups: group 1- IVER 400 plus DEC 1 mg.kg-1, 12 patients; group 2- IVER 400 plus DEC 3 mg.kg-1, 17 patients; group 3- IVER 400 plus DEC 6 mg.kg-1, 10 patients. Two control groups were included in the study, group 4- DEC 6 mg.kg-1 alone, 5 patients; group 5-: IVER 400 alone, 5 patients. Carriers were examined and questioned regarding their experience of adverse reactions, which were graded 0 to 3 according to severity, at 6, 12 and 24 hours and at 4 days after treatment. Biological examination was performed 4 days before and 4 days after treatment and included determination of microfilaremia, complete blood count, liver function tests and assessment of creatinine and urea levels. Adverse reactions were observed in 51% of 49 carriers (15 of grade 1, 8 of grade 2, 2 of grade 3). None was considered serious and they all disappeared in 2 days. The main symptoms were fever > or = 37.5 degrees C, myalgia, arthralgia, headache, asthenia, anorexia, vertigo and chills. Adverse reactions of patients were not significantly different between the five groups.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moulia-Pelat</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Institut Territorial de Recherches Medicales Louis Malarde, Papeete, Tahiti, Polynesie Francaise.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Glaziou</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chanteau</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gay</LastName><ForeName>V M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Cartel</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Trop Med Parasitol</MedlineTA><NlmUniqueID>8503728</NlmUniqueID><ISSNLinking>0177-2392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002353" MajorTopicYN="N">Carrier State</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008842" MajorTopicYN="N">Microfilariae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="Y">Wuchereria bancrofti</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8367670</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Polynésie française</li></country></list><tree><noCountry><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name><name sortKey="Chanteau, S" sort="Chanteau, S" uniqKey="Chanteau S" first="S" last="Chanteau">S. Chanteau</name><name sortKey="Gay, V M" sort="Gay, V M" uniqKey="Gay V" first="V M" last="Gay">V M Gay</name><name sortKey="Glaziou, P" sort="Glaziou, P" uniqKey="Glaziou P" first="P" last="Glaziou">P. Glaziou</name><name sortKey="Martin, P M" sort="Martin, P M" uniqKey="Martin P" first="P M" last="Martin">P M Martin</name><name sortKey="Nguyen, L N" sort="Nguyen, L N" uniqKey="Nguyen L" first="L N" last="Nguyen">L N Nguyen</name></noCountry><country name="Polynésie française"><noRegion><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004F71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:8367670
|texte= Safety trial of single-dose treatments with a combination of ivermectin and diethylcarbamazine in bancroftian filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:8367670" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |